Cortexyme to Present New Data at AAIC 2021
July 22 2021 - 7:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal
trial in Alzheimer’s disease with top-line data expected in the
fourth quarter of 2021 and a growing pipeline of therapeutics for
degenerative diseases, announced that it will present two
poster presentations covering an update from its pivotal Phase 2/3
GAIN Trial of atuzaginstat, in addition to new data demonstrating
the upstream role that P. gingivalis plays in key pathology of
Alzheimer’s disease, at the Alzheimer's Association International
Conference® 2021 (AAIC®) taking place July 26-30, 2021, in Denver,
Colorado, as well as virtually.
AAIC 2021 Poster Presentation Details
Topic: An update and baseline data from the Phase 2/3 GAIN trial
of COR388 (atuzaginstat), a novel bacterial virulence factor
inhibitor for the treatment of Alzheimer’s Disease
- Presenter: Michael Detke, MD, PhD, Cortexyme’s Chief Medical
Officer
- Authors: Michael Detke, MD, PhD1, Shirin Kapur, PhD1, Marwan
Sabbagh, MD2, Mark Ryder, DMD3, Ira Goodman, MD4, Debasish Raha,
PhD1, Florian Ermini, PhD1, Mai Nguyen, PhD1, Ursula Haditsch,
PhD1, Joanna Bolger1, Dave Hennings, PhD1, Kim Perry, PhD5, Kelly
Ritch, MS6, Casey Lynch1, Hatice Hasturk, DDS, PhD6, Leslie J.
Holsinger, PhD1, Stephen Dominy, MD1
Topic: Examining phospho-tau217 in neuron cultures and CVN mice
infected with Porphyromonas gingivalis and effects of gingipain
inhibition
- Presenter: Florian Ermini, PhD, Cortexyme’s Associate Director,
In Vivo Pharmacology and Translational Biology
- Authors1: Florian Ermini, PhD, Ursula Haditsch, PhD, Aurora
Martinez-Horta, Leo Rodriguez, Sean Broce, Mai Nguyen, PhD,
Debasish Raha, PhD, Shirin Kapur, PhD, Leslie Holsinger, PhD, Casey
Lynch, Stephen Dominy, MD
Cortexyme’s posters will be available on Monday, July 26, 2021,
beginning at 10:00 a.m. Eastern Time (8:00 a.m. Mountain Time) via
AAIC 2021’s virtual conference experience here, as well as on the
company’s website under the Science section accessible here.
Cortexyme AAIC Symposium – Getting to the Root Cause of
Alzheimer’s Disease
In conjunction with AAIC 2021, Cortexyme also will host a
corporate sponsored symposium and dinner titled “Getting to the
Root Cause of Alzheimer’s Disease: An Innovative, Upstream Approach
for Disease Modification” on Tuesday, July 27, 2021, from 5:30 p.m.
to 7:30 p.m. Mountain Time at the Hilton Denver City Center in
Denver, Colorado. Led by Cortexyme’s Chief Executive Officer,
Co-founder, and Chair Casey Lynch and Chief Medical Officer Michael
Detke, MD, PhD, the symposium will provide an informative
presentation on how Cortexyme is moving beyond the prevailing
targets to deliver a game-changing shift in Alzheimer’s disease
treatment. For AAIC 2021 registered participants wishing to attend
Cortexyme’s symposium in person, please email info@cortexyme.com to
sign up. The symposium may be accessed online by registering to
attend AAIC 2021 through its virtual conference experience
here.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
Alzheimer’s and other degenerative diseases. The company is
advancing its disease-modifying pivotal GAIN Trial in mild to
moderate Alzheimer's disease with top-line data expected in the
fourth quarter of 2021, in addition to growing a proprietary
pipeline of first-in-class small molecule therapeutics for
Parkinson’s disease, periodontitis, and other diseases with high
unmet clinical need. Cortexyme’s lead program targets a specific,
infectious pathogen called P. gingivalis found in the brain and
other organs and tied to degeneration and inflammation in humans
and animal models. The company’s causation evidence for Alzheimer’s
disease and the mechanism of its novel therapeutic has been
independently replicated and confirmed by multiple laboratories
around the world, as well as published in peer-reviewed scientific
journals. To learn more about Cortexyme, visit www.cortexyme.com or
follow @Cortexyme on Twitter.
Forward-Looking Statements
Statements in this news release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this news
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast,” or other similar words. Examples
of forward-looking statements include, among others, statements we
make regarding our business plans, strategy, timeline, prospects,
and milestone expectations; the timing and success of the company’s
clinical trials and related data, including with respect to the
GAIN and REPAIR Trials; the potential of atuzaginstat to treat
Alzheimer’s disease, periodontal disease, and other potential
indications; the timing of announcements and updates relating to
its clinical trials and related data; the potential therapeutic
benefits, safety and efficacy of the company’s product candidate or
library of compounds; and statements about its ability to obtain,
and the timing relating to, regulatory submissions and approvals
with respect to the company’s drug product candidate.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks, and
assumptions that are difficult to predict and could cause actual
results to differ materially from what the company expects.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Factors that could cause actual results to differ include, but are
not limited to, the risks and uncertainties described in the
section titled “Risk Factors” in Cortexyme’s Annual Report on Form
10-K filed with the Securities and Exchange Commission (SEC) on
March 1, 2021, its Quarterly Report on Form 10-Q filed with the SEC
on May 6, 2021, and other reports as filed with the SEC.
Forward-looking statements contained in this news release are made
as of this date, and Cortexyme undertakes no duty to update such
information except as required under applicable law.
(1) Cortexyme, South San Francisco, CA; (2) Cleveland Clinic,
Las Vegas; (3) UCSF, San Francisco, CA; (4) Bioclinica, Orlando,
FL; (5) Innovative Analytics, Portage, MI; (6) Datafy Clinical R
& D
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210722005319/en/
Stacy Roughan Cortexyme, Inc. Vice President, Corporate
Communications & Investor Relations ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024